If you are having trouble viewing this email, click on this link

Grant Writing Series - 2009

Grant Writing Series
Thursday, June 4, 2009 | 9:00 am -4:00pm | San Jose, CA

Shauna Farr-Jones, Ph.D
Forrest Blocker, Ph.D
Amy F. Boggs, Ph.D

· 9:00am: Registration
· 10:00am: Presentations
· 10:45am: General Q&A
· 11:00pm: Tour and Lunch
12:00pm: Private Meetings

Event Description
Join us for a 45 min initial presentation on grant writing basics and pitfalls. This discussion will cover general submissions and writing strategies, with a special focus on NIH SBIRs, as well as other agencies, grants, and deadlines. This event will be candid and very interactive. Following the presentation, the attendees will have an opportunity to meet with the presenter in a one-on-one meeting. Meetings will be scheduled on a first come first serve basis. For more information on PharmStatus, please visit http://www.pharmstatus.com.

What you will learn:
Why a grant?
· Eligibility
· How to get started
· Tips for a successful grant

Speaker Bios
Forrest Blocker, Ph.D., is a former academic with 20 years of experience in drug discovery and structural biology. In academia, she wrote extensively on structural determination of macromolecules using NMR and theory. She frequently consults and collaborates with scientists from various fields related to drug discovery. As a freelance consultant, she has been the point person to complete jobs requiring multiple types of expertise. She has experience in experimental physics and engineering, computer software and programming, statistical and data analysis, and editing and publishing. She has managed teams of medical writers, hardware technicians, and students.
Forrest is currently the President of the Northern California chapter of the American Medical Writer's Association.

Shauna Farr-Jones, Ph.D., has a record of writing successful government grant and contract proposals on diverse life science topics, providing strategic input on both research and business plans. For over eight years, she has consulted for life science companies and universities preparing research plans, marketing plans, IND’s, white papers and grant proposals. She also conducts technology assessment, competitive intelligence and primary market research on a wide variety of biotechnology platform technologies and disease therapeutic areas.

Amy F. Boggs, Ph.D., is an independent consultant with more than ten years experience in anti-infective drug discovery and development. In addition to grant-writing, she provides companies with help in the preparation of technical reports, INDs and NDAs, technology assessment, strategic research planning, and competitive landscaping. Prior to her work as a consultant, Dr. Boggs worked at Microcide and at IntraBiotics, where she managed an interdisciplinary technology in-licensing team that resulted in three screening technology partnerships and two product in-licenses. Dr. Boggs is an inventor on three issued patents and has worked on investigational new drug (IND)-enabling projects.

San Jose BioCenter
5941 Optical Ct.
San Jose, CA 95138
Click here for Venue Directions»

Upcoming BioCenter Events

Making Yourself a Target
Thursday, June 11, 2009 | 3:00 - 6:30pm | San Jose, CA

Confirmed Speakers
Mark Edwards, Principal, Deloitte Recap LLC
Peter Condon, Associate Director Business Development, Genentech
Sara Hall, CEO, Tacere Therapeutics
Lee Bendekgey, former CFO and General Counsel, Nuvelo
Jim Schaeffer, Executive Director, Licensing And External Research, Merck Research Laboratories, Merck & Co., Inc.
Lead Facilitator: Gregory Heibel, Partner, Orrick

Event Description
Partnerships are on the rise, and businesses throughout the industry are preparing their next steps.  Big BioTech companies have the power to purchasing 2009 intellect for 1999 prices.  Find out what it takes to make your business attractive to larger companies, while maintaining worth.  Discover who’s looking, and how to become a target.  Join this panel to hear strategic perspectives from the purchased, the purchaser, the investor, and the lawyer. 

This event will be held at:

Orrick, Herrington & Sutcliffe LLP
1000 Marsh Road
Building 1100
Menlo Park, CA 94025-1015
Click here for Venue Directions»


Event Sponsor:

Meet With … Takeda Research Investment- July 14, 2009
Takeda Research Investment, Inc. (TRI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC) a world-class pharmaceutical company and the largest in Japan. A wholly-owned subsidiary of Takeda America Holdings, Inc., TRI started operations in 2002. Our aim is to encourage and support therapeutic innovation in biopharmaceutical companies and academic centers of excellence, through early stage capital investment and provision of access to the resources of a multinational pharmaceutical company. Read more

Industry Events

BioMarker World Congress - May 27-29, 2009 – Cambridge Healthtech Institute - Philadelphia, PA

20th Annual Venture Capital Investing Conference - June 3-5,2009 - International Business Forum - San Francisco, CA

Personalized Medicine 2.0 - Bioinformatics: Mining the Data - June 4, 2009 - San Francisco State University - San Francisco, CA

Grant Writing Seminar - June 4, 2009 - San Jose BioCenter - San Jose, CA

Making Yourself a Target - June 11, 2009 - San Jose BioCenter - San Jose, CA

Life Science CEO Panel: From Strategy to Execution - June 15, 2009 - FountainBlue - Palo Alto, CA

The Road to $30M and Beyond: A Cleantech Story - June 16, 2009 - Environmental Business Cluster - San Jose, CA

California Green Chemistry Initiative - June 29, 2009 - San Jose BioCenter - Menlo Park, CA

BIOPharma America 2009- September 16 - 18, 2009

BIO-Europe - November 2 - 4, 2009

  Sponsors & Founding Parnters  




2004-2009 San Jose BioCenter, All Rights Reserved. | [email protected]
5941 Optical Court, San Jose, CA 95138 | (408) 960-3807
You are receiving this email from San Jose BioCenter because we met you and thought you could be interested in the above information, or because you subscribed on our website.
If the above information is not of interest to you, please disregard and we apologize for any inconvenience this may have caused.
To be removed from further emails, please click on the "SafeUnsubscribe" link below.